男性复杂性尿路感染门诊首选推荐治疗的年龄、种族与族裔差异
该研究基于美国退伍军人事务部(VA)门诊2010至2020年157,898例男性尿路感染患者的回顾性队列,评估年龄、种族和族裔与推荐首选治疗(一线药物且疗程7-10天)的关系。仅50.6%患者接受推荐首选治疗,18-49岁较≥65岁更可能接受推荐首选治疗(aOR 1.07,95%CI 1.03-1.11),未发现种族和族裔差异。
要点
- 仅50.6%男性复杂性尿路感染门诊患者接受推荐首选治疗(一线药物且疗程7-10天)。
- 18-49岁患者较≥65岁患者更可能接受推荐首选治疗(aOR 1.07,95%CI 1.03-1.11)。
- 未发现种族和族裔差异,但推荐首选治疗使用不足仍是抗菌药物管理重点。
核心结论
- 近半数男性复杂性尿路感染门诊患者未接受推荐首选治疗,但未发现种族和族裔差异。
研究设计与样本
- 全国性回顾性队列研究,纳入2010年1月至2020年12月VA门诊诊断为尿路感染并接受门诊抗生素处方的男性患者157,898例。
主要发现
- 平均抗生素疗程9.4天(标准差4.6天)。
- 47.6%患者使用环丙沙星,25.1%使用磺胺甲噁唑/甲氧苄啶,7.6%使用呋喃妥因,6.6%使用左氧氟沙星。
- 50.6%(n=79,928)接受推荐首选治疗(一线药物且合适疗程),77.6%(n=122,590)接受推荐抗生素选择,65.9%(n=104,070)接受推荐疗程。
- 18-49岁较≥65岁是唯一预测推荐首选治疗的人口学因素(aOR 1.07,95%CI 1.03-1.11)。
关键数值与推荐
- 推荐首选治疗定义为使用推荐一线抗生素(环丙沙星、左氧氟沙星或磺胺甲噁唑/甲氧苄啶)且疗程7-10天,不考虑感染部位。
临床怎么用
- 临床应关注男性复杂性尿路感染门诊患者推荐首选治疗的使用不足,尤其是≥65岁患者。
- 抗菌药物管理项目应继续聚焦提高推荐首选抗生素和合适疗程的使用率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There are known disparities in the treatment of infectious diseases. However, disparities in treatment of complicated urinary tract infections (UTIs) are largely uninvestigated. OBJECTIVES: We characterized UTI treatment among males in Veterans Affairs (VA) outpatient settings by age, race, and ethnicity and identified demographic characteristics predictive of recommended first-choice antibiotic therapy. METHODS: We conducted a national, retrospective cohort study of male VA patients diagnosed with a UTI and dispensed an outpatient antibiotic from January 2010 through December 2020. Recommended first-choice therapy for complicated UTI was defined as use of a recommended first-line antibiotic drug choice regardless of area of involvement (ciprofloxacin, levofloxacin, or sulfamethoxazole/trimethoprim) and a recommended duration of 7 to 10 days of therapy. Multivariable models were used to identify demographic predictors of recommended first-choice therapy (adjusted odds ratio [aOR] > 1). RESULTS: We identified a total of 157,898 males diagnosed and treated for a UTI in the outpatient setting. The average antibiotic duration was 9.4 days (±standard deviation [SD] 4.6), and 47.6% of patients were treated with ciprofloxacin, 25.1% with sulfamethoxazole/trimethoprim, 7.6% with nitrofurantoin, and 6.6% with levofloxacin. Only half of the male patients (50.6%, n = 79,928) were treated with recommended first-choice therapy (first-line drug choice and appropriate duration); 77.6% (n = 122,590) were treated with a recommended antibiotic choice and 65.9% (n = 104,070) with a recommended duration. Age 18-49 years (aOR 1.07, 95% confidence interval [CI] 1.03-1.11) versus age ≥65 years was the only demographic factor predictive of recommended first-choice therapy. CONCLUSIONS: Nearly half of the patients included in this study did not receive recommended first-choice therapies; however, racial and ethnic disparities were not identified. Underutilization of recommended first-choice antibiotic therapy in complicated UTIs continues to be an area of focus for antimicrobial stewardship programs.
引用
- Sine K, Lavoie T, Caffrey AR, et al. Exploring variations in recommended first-choice therapy for complicated urinary tract infections in males: Insights from outpatient settings across age, race, and ethnicity. Pharmacotherapy. 2024. PMID: 38483080. doi:10.1002/phar.2912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。